Human epidermal growth factor receptor 2 (HER2), a member of the epidermal growth factor receptor (EGFR) family, is overexpressed in approximately 20–30 % of human breast cancers, and its expression is associated with poor patient prognosis [1]. This evidence concerns the gene ERBB2 and breast carcinoma.